Valneva SE (VALN) Shares Outstanding (2019 - 2026)
Valneva SE (VALN) posted quarterly Shares Outstanding (Entity) of $95.7 million for Q4 2025, up 15.42% year-on-year from $82.9 million in Q4 2024, and down 1.18% on a QoQ basis from $96.8 million in Q2 2025.
Valneva SE (VALN) Shares Outstanding (2019 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Shares Outstanding (Entity) for 7 consecutive years, with $95.7 million the latest figure, recorded in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 15.42% year-over-year to $95.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $95.7 million (up 15.42% YoY) and the FY2025 annual result came in at $95.7 million, up 15.42% from the prior year.
- Shares Outstanding (Entity) slipped to $95.7 million in Q4 2025 per VALN's latest filing, from $96.8 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for VALN reached as high as $96.8 million in Q2 2025 and fell as low as $634389.0 in Q2 2022.
- A 5-year average of $66.3 million and a median of $66.2 million in 2022 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) plunged 98.88% — and 2023, when it jumped 12357.5%.
- Year by year, Shares Outstanding (Entity) stood at $55.5 million in 2021, then climbed by 18.29% to $65.7 million in 2022, then gained by 20.05% to $78.9 million in 2023, then rose by 5.11% to $82.9 million in 2024, then rose by 15.42% to $95.7 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $95.7 million, $96.8 million, and $82.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6,012.74 Bn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 47.82 Bn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.44 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 11.23 Bn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 254.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 400.00 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 62.19 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 198.10 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 168.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 168.18 Mn |
| Dec 31, 2025 | 168.18 Mn |
| Sep 30, 2025 | 145.71 Mn |
| Jun 30, 2025 | 145.71 Mn |
| Mar 31, 2025 | 145.71 Mn |
| Dec 31, 2024 | 145.71 Mn |
| Sep 30, 2024 | 138.62 Mn |
| Jun 30, 2024 | 138.62 Mn |
| Mar 31, 2024 | 138.62 Mn |
| Dec 31, 2023 | 138.62 Mn |
| Sep 30, 2023 | 115.47 Mn |
| Jun 30, 2023 | 115.47 Mn |
| Mar 31, 2023 | 115.47 Mn |
| Dec 31, 2022 | 115.47 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 1.11 Mn |
| Mar 31, 2022 | 97.62 Mn |
| Dec 31, 2021 | 97.62 Mn |
| Sep 30, 2021 | 90.76 Mn |
| Jun 30, 2021 | 90.76 Mn |